MyAverix Finance MyAverix Finance

SA

CRISPR Therapeutics AG (C2RS34)

CRISPR Therapeutics AG (C2RS34) is listed on SA. As of 2026-05-23, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-05-23

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for C2RS34

P/E ratio
18.00

CRISPR Therapeutics AG (C2RS34) — FAQ

What is C2RS34's P/E ratio?

The price-to-earnings (P/E) ratio for CRISPR Therapeutics AG (C2RS34) is 18.00 (data as of 2026-05-23).

Does CRISPR Therapeutics AG pay a dividend?

Dividend yield is not available in the current snapshot for CRISPR Therapeutics AG (C2RS34). Check the MyAverix Finance app for the latest dividend data.

What exchange is C2RS34 listed on?

C2RS34 is listed on SA.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play